Affymetrix Announces Completion of Smallpox Array Set Developed with CDC
February 19 2004 - 5:00AM
PR Newswire (US)
Affymetrix Announces Completion of Smallpox Array Set Developed
with CDC - Seven-Array Set Will Enable Rapid Resequencing of the
Entire Smallpox Genome - SANTA CLARA, Calif., Feb. 19
/PRNewswire-FirstCall/ -- Affymetrix, Inc., today announced the
completion of the GeneChip(R) brand Smallpox Resequencing Array
Set, seven smallpox arrays that will enable rapid resequencing of
the entire smallpox genome. These arrays, developed in
collaboration with the Centers for Disease Control and Prevention
(CDC), contain genomic sequence common to all strains of smallpox,
as well as variant DNA from different smallpox isolates. The
Affymetrix Smallpox Resequencing Array Set will be used to identify
and catalog hundreds of different smallpox strains within the World
Health Organization collection maintained at the CDC and will also
help researchers differentiate smallpox from other orthopox viruses
like monkeypox or cowpox. The smallpox array set can potentially be
used to quickly identify a new smallpoxstrain as well as determine
if a particular strain has been genetically engineered. The array
set may also have clinical applications, such as epidemiological
studies and vaccine research. "This array set joins a growing list
of pathogen arrays developed using the CustomSeq(TM) Array Program,
including a SARS virus array and numerous other custom arrays,"
said Greg Yap, Senior Marketing Director, DNA Analysis. "Through
this program, researchers can design custom arrays to completely
resequence an entire viral organism, such as SARS or smallpox, or
design a single array to interrogate unique sequences from multiple
pathogens." Pathogen arrays can be used to identify and catalog
outbreaks, as well as to compare patient outcome among different
pathogen subtypes. Such arrays allow scientists to better
understand which strains are most dangerous and to discover key
factors in developing therapies. In addition, epidemiologists can
use the arrays to study how viruses are evolving over time, during
their spread into different geographies and populations. One
CustomSeq array can sequence about 30,000 bases of unique sequence
quickly and with a high degree of accuracy. Compared to capillary
methods, CustomSeq arrays make sequencing faster and more effective
by delivering completed sequence with minimal assembly and
alignment. Understanding pathogens is one of many CustomSeq array
applications. Other uses of CustomSeq arrays include SNP discovery,
comparative sequencing of drug targets and investigation of
candidate gene regions. For more information about CustomSeq
resequencing arrays, customers may contact their Affymetrix Sales
Representative, or point their browsers to
http://www.affymetrix.com/. About Affymetrix: Affymetrix is a
pioneer increating breakthrough tools that are driving the genomic
revolution. By applying the principles of semiconductor technology
to the life sciences, Affymetrix develops and commercializes
systems that enable scientists to improve quality of life. The
Company's customers include pharmaceutical, biotechnology,
agrichemical, diagnostics and consumer products companies as well
as academic, government and other non-profit research institutes.
Affymetrix offers an expanding portfolio of integrated productsand
services, including its integrated GeneChip platform, to address
growing markets focused on understanding the relationship between
genes and human health. Additional information on Affymetrix can be
found at http://www.affymetrix.com/. All statements in this press
release that are not historical are "forward- looking statements"
within the meaning of Section 21E of the Securities Exchange Act as
amended, including statements regarding Affymetrix' "expectations,"
"beliefs," "hopes," "intentions,""strategies" or the like. Such
statements are subject to risks and uncertainties that could cause
actual results to differ materially for Affymetrix from those
projected, including, but not limited to risks of the Company's
ability to achieve and sustain higher levels of revenue, higher
gross margins, reduced operating expenses, uncertainties relating
to technological approaches, manufacturing, product development,
market acceptance (including uncertainties relating to product
development and marketacceptance of the Affymetrix Smallpox
Resequencing Array Set), personnel retention, uncertainties related
to cost and pricing of Affymetrix products, dependence on
collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory
approvals, competition, risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2002 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix, Inc. DATASOURCE:
Affymetrix, Inc. CONTACT: Wes Conard, Associate Director, Public
Relations, +1-408-731-5791, or investors, Doug Farrell, Vice
President, Investor Relations, +1-408-731-5285, both of Affymetrix,
Inc. Web site: http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024